Article
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.
Cancer cell - 8 May 2023
Chen Yan-Xing, Wang Zi-Xian, Jin Ying, Zhao Qi, Liu Ze-Xian, Zuo Zhi-Xiang, Ju Huai-Qiang, Cui Chengxu, Yao Jun, Zhang Yanqiao, Li Mengxia, Feng Jifeng, Tian Lin, Xia Xiao-Jun, Feng Hui, Yao Sheng, Wang Feng-Hua, Li Yu-Hong, Wang Feng, Xu Rui-Hua
Abstract excerpt
Although chemotherapy plus PD-1 blockade (chemo+anti-PD-1) has become the standard first-line therapy for advanced esophageal squamous cell carcinoma (ESCC), reliable biomarkers for this regimen are lacking. Here we perform whole-exome sequencing on tumor samples from 486 patients of the JUPITER-06 study and develop a copy number alteration-corrected tumor mutational burden that depicts immunogenicity more...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.